Pharmaceutical company Achillion Pharmaceuticals Inc (Nasdaq:ACHN) revealed on Thursday that the company has initiated patient dosing in a Phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) infection.
The company added that ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication.
This Phase IIa, randomised, double-blind, placebo-controlled trial will evaluate the safety, tolerability and antiviral activity of oral ACH-1625 in combination with pegylated interferon alfa-2a and ribavirin after 28 days of dosing and after 12 weeks of dosing in subjects with chronic hepatitis C virus genotype 1.
Additionally, the company stated that the trial will take place in the US and Europe and the data is anticipated in the first and fourth quarters of 2011, respectively.
Posts
No comments:
Post a Comment